ici 118551 has been researched along with Multiple Hemangioblastomas in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Albiñana, V; Botella, LM; Cuesta, AM; González-Peramato, P; Martinez-Piñeiro, L; Recio-Poveda, L | 1 |
| Aguirre, DT; Albiñana, V; Botella, LM; Cuesta, AM; de Las Heras, KVG; de Rojas-P, I; Gallardo-Vara, E; Recio-Poveda, L | 1 |
2 other study(ies) available for ici 118551 and Multiple Hemangioblastomas
| Article | Year |
|---|---|
Blockade of β2-Adrenergic Receptor Reduces Inflammation and Oxidative Stress in Clear Cell Renal Cell Carcinoma.
Topics: Animals; Carcinoma, Renal Cell; Cell Line, Tumor; Gene Expression Regulation, Neoplastic; Hemangioblastoma; Humans; Inflammation; Kidney Neoplasms; Male; Mice; Oxidative Stress; Propanolamines; Propranolol; Receptors, Adrenergic, beta-2; Signal Transduction; von Hippel-Lindau Disease; Von Hippel-Lindau Tumor Suppressor Protein | 2022 |
The β2-adrenergic receptor antagonist ICI-118,551 blocks the constitutively activated HIF signalling in hemangioblastomas from von Hippel-Lindau disease.
Topics: Adrenergic beta-Antagonists; Apoptosis; Cell Nucleus; Central Nervous System Neoplasms; Hemangioblastoma; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Molecular Targeted Therapy; Mutation; Neovascularization, Pathologic; Propanolamines; Signal Transduction; Tumor Cells, Cultured; von Hippel-Lindau Disease; Von Hippel-Lindau Tumor Suppressor Protein | 2019 |